Crispr Therapeutics Ag

We track 6 ClinicalTrials.gov studies led by Crispr Therapeutics Ag. The portfolio skews toward Phase 1 (4 trials).

6 clinical trials sponsored by Crispr Therapeutics Ag.

Pipeline by Phase

PhaseTrialsDistribution
Phase 1 4
67%
Phase 2 2
33%

Trial Status Breakdown

Trials by Crispr Therapeutics Ag

A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias

NCT07491172 · RECRUITING · Phase 1

A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies

NCT05643742 · RECRUITING · Phase 2

A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Relapsed or Refractory T or B Cell Malignancies

NCT04502446 · TERMINATED · Phase 1

A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation

NCT04438083 · TERMINATED · Phase 1

A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) in Subjects With Relapsed or Refractory Multiple Myeloma

NCT04244656 · TERMINATED · Phase 1

A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

NCT04035434 · TERMINATED · Phase 2

Frequently Asked Questions

How many clinical trials does Crispr Therapeutics Ag sponsor?

Crispr Therapeutics Ag currently sponsors 6 clinical trials tracked on ReadTheTrial. These span Phase 1, Phase 2.

What conditions does Crispr Therapeutics Ag research?

Crispr Therapeutics Ag conducts research across multiple therapeutic areas. Browse the trial listings for details.

Is Crispr Therapeutics Ag recruiting for clinical trials?

Yes, Crispr Therapeutics Ag currently has 2 trials that are actively recruiting participants. Check individual trial pages for eligibility criteria and locations.

Explore More